Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347968 · ClinicalTrials.gov registry record · Phase 1
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03347968 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 22 participants.
The verdict
NCT03347968, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
Interventions
- DRUG Warfarin
- DRUG Esmolol
- BIOLOGICAL MEDI0382
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347968
The ClinicalTrials.gov registry entry for NCT03347968 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT03347968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03347968 about?
NCT03347968 is a clinical study titled "Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382". A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
What is the current status of trial NCT03347968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-11-27. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT03347968?
The interventions under investigation include: Warfarin (DRUG), Esmolol (DRUG), MEDI0382 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03347968?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.